FDA approves AstraZeneca's Epanova, label update for Teva's Synribo; Researchers head to Twitter to identify drug problems;

> The FDA has green-lighted AstraZeneca's ($AZN) Epanova as a treatment for severe hypertriglyceridaemia in adults. Release

> The FDA has approved a label change for Teva's ($TEVA) Synribo injection that allows for home administration. Release

> A 6-week marketing suspension on Ariad's ($ARIA) chronic myeloid leukemia drug Iclusig has not negatively impacted how physicians view the drug, a survey found. More

> The U.S. diabetes market will reach $25 billion by 2020, with Sanofi ($SNY), Novo Nordisk ($NVO) and Eli Lilly ($LLY) leading the way, a new report says. Release

> An FDA panel will meet in October to review the risks of psychiatric and behavioral side effects associated with Pfizer's ($PFE) antismoking med Chantix. More

And Finally... Researchers have found that tapping into Twitter to read patient posts describing medication side effects could help them identify problems with drugs sooner. Story